BP-897 is a drug used in scientific research which acts as a potent selective
dopamineD3receptorpartial agonist with an
in vitrointrinsic activity of ~0.6 and ~70x greater affinity for D3 over D2 receptors and is suspected to have partial agonist or antagonist activity
in vivo.[1] It has mainly been used in the study of treatments for
cocaine addiction.[2][3][4][5][6][7][8] A study comparing BP-897 with the potent, antagonistic, and highly D3 selective
SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."[9]
References
^Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. (July 1999). "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature. 400 (6742): 371–375.
doi:
10.1038/22560.
PMID10432116.
S2CID4351316.
^Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (November 2004). "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics. 311 (2): 770–777.
doi:
10.1124/jpet.104.071142.
PMID15226382.
S2CID15481124.
^Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P (May 2008). "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem. 3 (5): 788–793.
doi:
10.1002/cmdc.200700327.
PMID18306190.
S2CID23143152.